leon-nanodrugs appoints Dr. Hans Frickel as Chief Executive Officer

leon-nanodrugs appoints Dr. Hans Frickel as Chief Executive Officer

 July 18, 2023 – Munich (Germany) – leon-nanodrugs GmbH (“LEON”), the leading enabler of nano technology for the pharmaceutical industry, announced today the appointment of Dr. Hans Frickel as CEO, effective July 1, 2023. Dr. Hans Frickel, a trained pharmacist and industrial manager, brings more than 20 years of experience in strategic and operational leadership roles across the entire value chain of pharmaceuticals and medical devices. Prior to joining LEON, he served as Managing Director at R‑Biopharm and held several senior operational management roles at BioNTech, Evonik, Midas Pharma, Procter & Gamble and Merck.

Dr. Hubert Birner, Chairman of the LEON Supervisory Board, said: “On behalf of the Supervisory Board, I am delighted to welcome Dr. Hans Frickel to LEON. With his extensive expertise in different areas of modern drug manufacturing, including plant management and QC, as well as a strong track record in strategy and governance, he is an ideal fit to take LEON to the next stage. On behalf of the Supervisory Board I also would like to thank our interim CEO and CFO Christian Nafe, our CSO Dr. Setu Kasera and their team for their tremendous work in driving our technology towards commercialization and for the great progress that has been achieved to date.”

“I am excited to join LEON as we work to transform nanomedicine manufacturing,” said Dr. Hans Frickel, CEO of LEON. “I am impressed with the team’s knowledge and dedication in working to create added value across the nano formulation processing chain. I truly believe that LEON’s NANO devices will significantly improve development and manufacturing for current and future standardized and personalized cell & gene therapies at CDMOs, biotech and pharma companies.”
 

ABOUT LEON-NANODRUGS

leon-nanodrugs GmbH (“LEON”) is a pharmatech company specializing in the development and marketing of devices for the encapsulation of genetic material and other active substances into nanodrug carriers, such as lipid nanoparticles (LNPs). The Munich-based private company builds its innovative solutions based on its proprietary FR-JET Technology, enabling pharma companies and small biotechs as well as CDMOs to optimize nanomedicine manufacturing and take full advantage of the significant progress being made in advanced therapies.

LEON's GMP-compliant, aseptic devices NANOme and NANOus increase efficiency in the production of nano drug carriers and are suitable for both clinical-scale and commercial production. In addition to its product offering, LEON will provide in-house lab capacity for process development with its own devices.

For further information, please visit https://leon-nanodrugs.com/ and follow us on LinkedIn and Twitter.
 

For a high-res picture please contact leon-nanodrugs@mc-services.eu.